Niagen Bioscience (NAGE) EBT Margin (2010 - 2026)

Niagen Bioscience (NAGE) has 17 years of EBT Margin data on file, last reported at 21.4% in Q1 2026.

• On a quarterly basis, EBT Margin rose 424.0% year-over-year to 21.4% in Q1 2026; TTM through Mar 2026 was 15.1%, a 159.0% increase from a year earlier, with the FY2025 full-year figure at 14.06%, up 517.0% from the prior year.
• EBT Margin for Q1 2026 stood at 21.4%, up from 13.07% in the prior quarter.
• Over the last five years, EBT Margin for NAGE reached as high as 25.7% in Q4 2024 and fell as low as 69.67% in Q2 2022.
• Historically, EBT Margin has averaged 9.17% across 5 years, with a median of 1.27% in 2023.
• Across the five-year window, EBT Margin tumbled 1495 bps in 2022 and jumped 3624 bps in 2023, its largest moves.
• Year by year, EBT Margin stood at 7.52% in 2022, then jumped by 83 bps to 1.27% in 2023, then surged by 2117 bps to 25.7% in 2024, then sank by 49 bps to 13.07% in 2025, then surged by 64 bps to 21.4% in 2026.
• Per Business Quant data, the three most recent EBT Margin figures were 21.4% in Q1 2026, 13.07% in Q4 2025, and 14.12% in Q3 2025.